309 related articles for article (PubMed ID: 32678966)
21. The Roles of Inflammation in Keloid and Hypertrophic Scars.
Wang ZC; Zhao WY; Cao Y; Liu YQ; Sun Q; Shi P; Cai JQ; Shen XZ; Tan WQ
Front Immunol; 2020; 11():603187. PubMed ID: 33343575
[TBL] [Abstract][Full Text] [Related]
22. N-Acetyl-Seryl-Asparyl-Lysyl-Proline regulates lung renin angiotensin system to inhibit epithelial-mesenchymal transition in silicotic mice.
Li S; Li Y; Zhang Y; Li S; Zhang M; Jin F; Wei Z; Yang Y; Gao X; Mao N; Ge X; Xu H; Yang F
Toxicol Appl Pharmacol; 2020 Dec; 408():115255. PubMed ID: 33007385
[TBL] [Abstract][Full Text] [Related]
23. Smad interacting protein 1 as a regulator of skin fibrosis in pathological scars.
Zhang ZF; Zhang YG; Hu DH; Shi JH; Liu JQ; Zhao ZT; Wang HT; Bai XZ; Cai WX; Zhu HY; Tang CW
Burns; 2011 Jun; 37(4):665-72. PubMed ID: 21236582
[TBL] [Abstract][Full Text] [Related]
24. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Weber MA
J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
[TBL] [Abstract][Full Text] [Related]
25. The Most Current Algorithms for the Treatment and Prevention of Hypertrophic Scars and Keloids: A 2020 Update of the Algorithms Published 10 Years Ago.
Ogawa R
Plast Reconstr Surg; 2022 Jan; 149(1):79e-94e. PubMed ID: 34813576
[TBL] [Abstract][Full Text] [Related]
26. Epithelial-mesenchymal transition in the formation of hypertrophic scars and keloids.
Yuan FL; Sun ZL; Feng Y; Liu SY; Du Y; Yu S; Yang ML; Lv GZ
J Cell Physiol; 2019 Dec; 234(12):21662-21669. PubMed ID: 31106425
[TBL] [Abstract][Full Text] [Related]
27. Periostin is induced by IL-4/IL-13 in dermal fibroblasts and promotes RhoA/ROCK pathway-mediated TGF-β1 secretion in abnormal scar formation.
Maeda D; Kubo T; Kiya K; Kawai K; Matsuzaki S; Kobayashi D; Fujiwara T; Katayama T; Hosokawa K
J Plast Surg Hand Surg; 2019 Oct; 53(5):288-294. PubMed ID: 31066603
[TBL] [Abstract][Full Text] [Related]
28. Topical tamoxifen therapy in hypertrophic scars or keloids in burns.
Gragnani A; Warde M; Furtado F; Ferreira LM
Arch Dermatol Res; 2010 Jan; 302(1):1-4. PubMed ID: 19636578
[TBL] [Abstract][Full Text] [Related]
29. [Role of angiotensin II receptors in proliferation of fibroblast derived from human hypertrophic scars].
Liu HW; Cheng B; Yu WL; Sun RX; Tang JB; Fu XB
Zhonghua Zheng Xing Wai Ke Za Zhi; 2007 Jan; 23(1):36-9. PubMed ID: 17393691
[TBL] [Abstract][Full Text] [Related]
30. Genetic susceptibility to keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels.
Bayat A; Bock O; Mrowietz U; Ollier WE; Ferguson MW
Plast Reconstr Surg; 2003 Feb; 111(2):535-43; discussion 544-6. PubMed ID: 12560674
[TBL] [Abstract][Full Text] [Related]
31. Endothelial cell-derived endothelin-1 is involved in abnormal scar formation by dermal fibroblasts through RhoA/Rho-kinase pathway.
Kiya K; Kubo T; Kawai K; Matsuzaki S; Maeda D; Fujiwara T; Nishibayashi A; Kanazawa S; Yano K; Amano G; Katayama T; Hosokawa K
Exp Dermatol; 2017 Aug; 26(8):705-712. PubMed ID: 27892645
[TBL] [Abstract][Full Text] [Related]
32. Keloids are transcriptionally distinct from normal and hypertrophic scars.
Walter AS; Stocks M; Akova E; Gauglitz G; Hartmann D; Aszodi A; Böcker W; Saller MM; Volkmer E
Eur J Dermatol; 2023 Dec; 33(6):604-611. PubMed ID: 38465540
[TBL] [Abstract][Full Text] [Related]
33. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
[TBL] [Abstract][Full Text] [Related]
34. Local renin-angiotensin system molecular mechanisms in intrauterine adhesions formation following gynecological operations, new strategy for novel treatment.
Shabanian S; Khazaie M; Ferns GA; Arjmand MH
J Obstet Gynaecol; 2022 Aug; 42(6):1613-1618. PubMed ID: 35260037
[TBL] [Abstract][Full Text] [Related]
35. Hypertrophic and keloid scars fail to progress from the CD34
Limandjaja GC; Belien JM; Scheper RJ; Niessen FB; Gibbs S
Br J Dermatol; 2020 Apr; 182(4):974-986. PubMed ID: 31206605
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinase-2 and -9 activities in human keloids, hypertrophic and atrophic scars: a pilot study.
Tanriverdi-Akhisaroglu S; Menderes A; Oktay G
Cell Biochem Funct; 2009 Mar; 27(2):81-7. PubMed ID: 19165813
[TBL] [Abstract][Full Text] [Related]
37. Treatment of scars: a review.
Alster TS; West TB
Ann Plast Surg; 1997 Oct; 39(4):418-32. PubMed ID: 9339286
[TBL] [Abstract][Full Text] [Related]
38. [Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases].
Huber K; Pachinger O; Pichler M; Klein W
Z Kardiol; 1997 Apr; 86(4):239-50. PubMed ID: 9235795
[TBL] [Abstract][Full Text] [Related]
39. Wnt Signaling Pathway Proteins in Scar, Hypertrophic Scar, and Keloid: Evidence for a Continuum?
Chaudet KM; Goyal A; Veprauskas KR; Nazarian RM
Am J Dermatopathol; 2020 Nov; 42(11):842-847. PubMed ID: 32310858
[TBL] [Abstract][Full Text] [Related]
40. Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment.
Berman B; Maderal A; Raphael B
Dermatol Surg; 2017 Jan; 43 Suppl 1():S3-S18. PubMed ID: 27347634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
